



1.FW

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/682,331
	Filing Date	October 8, 2003
	First Named Inventor	David L. SHELTON
	Art Unit	1641
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	43 + 233 Refs.	Attorney Docket Number 514712000400

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address (1 page) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (17 pages in duplicate) 2. Statement Under 37 CFR 3.73(b) w/copy of Assignment (4 pages total) 3. References (233) 4. Return receipt postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Jie Zhou - 52,395 (Customer No. 25226)
Signature	
Date	June 23, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: June 23, 2004	Signature: (Martina Placid)



PATENT
Docket No. 514712000400

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 23, 2004.

Martina Placid

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David L. SHELTON et al.

Serial No.: 10/682,331

Filing Date: October 8, 2003

For: METHODS FOR TREATING POST-
SURGICAL PAIN BY
ADMINISTERING A NERVE GROWTH
FACTOR ANTAGONIST AND
COMPOSITIONS CONTAINING THE
SAME

Examiner: Not Yet Assigned

Group Art Unit: 1641

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith.

Copies of co-pending applications are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 514712000400. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 23, 2004

Respectfully submitted,

By: 
Jie Zhou
Registration No. 52,395

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5922
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 514712000400

Application Number 10/682,331


Applicant

David L. SHELTON et al.

Filing Date October 8, 2003

Group Art Unit 1641

Mailing Date June 23, 2004

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/08/2003	10/682,332	Shelton et al.			
	2.	10/08/2003	10/682,638	Shelton et al.			
	3.	12/24/2003	10/745,775	Pons et al.			
	4.	02/19/2004	10/783,730	Shelton et al.			
	5.	03/01/2004	10/791,162	Shelton et al.			
	6.	11/29/2001	2001/0046959	Buchovich et al.			
	7.	03/07/2002	2002/0028779	High et al.			
	8.	11/20/1973	3,773,919	Boswell et al.			
	9.	11/27/1984	4,485,045	Regen			
	10.	10/01/1985	4,544,545	Ryan et al.			
	11.	06/30/1987	4,676,980	Segal et al.			
	12.	07/28/1987	4,683,195	Mullis et al.			
	13.	07/28/1987	4,683,202	Mullis			
	14.	06/28/1988	4,754,065	Levenson et al.			
	15.	10/11/1988	4,777,127	Suni et al.			
	16.	01/24/1989	4,800,159	Mullis et al.			
	17.	03/28/1989	4,816,567	Cabilly et al.			
	18.	05/07/1991	5,013,556	Woodle et al.			
	19.	09/10/1991	5,047,335	Paulson et al.			
	20.	07/14/1992	5,130,311	Guillaumet et al.			
	21.	09/15/1992	5,147,294	Smith et al.			
	22.	06/15/1993	5,219,740	Miller et al.			
	23.	01/11/1994	5,278,299	Wong et al.			
	24.	08/30/1994	5,342,942	Jaen et al.			
	25.	04/25/1995	5,409,944	Black et al.			
	26.	06/06/1995	5,422,120	Kim			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 514712000400		Application Number 10/682,331	
				Applicant David L. SHELTON et al.			
				Filing Date October 8, 2003		Group Art Unit 1641	
				Mailing Date June 23, 2004			

	27.	07/25/1995	5,436,265	Black et al.			
	28.	12/19/1995	5,475,995	Livingston			
	29.	03/19/1996	5,500,362	Robinson et al.			
	30.	04/23/1996	5,510,261	Goochee et al.			
	31.	04/23/1996	5,510,368	Lau et al.			
	32.	05/28/1996	5,521,213	Prasit et al.			
	33.	06/25/1996	5,530,101	Queen et al.			
	34.	07/16/1996	5,536,752	Ducharme et al.			
	35.	08/13/1996	5,545,806	Lonberg et al.			
	36.	08/13/1996	5,545,807	Surani et al.			
	37.	08/27/1996	5,550,142	Ducharme et al.			
	38.	09/03/1996	5,552,422	Gauthier et al.			
	39.	10/15/1996	5,565,332	Hoogenboom et al.			
	40.	10/29/1996	5,569,825	Lonberg et al.			
	41.	12/03/1996	5,580,717	Dower et al.			
	42.	12/03/1996	5,580,859	Felgner et al.			
	43.	12/17/1996	5,585,089	Queen et al.			
	44.	01/14/1997	5,593,994	Batt et al.			
	45.	02/18/1997	5,604,253	Lau et al.			
	46.	02/18/1997	5,604,260	Guay et al.			
	47.	04/01/1997	5,616,601	Khanna et al.			
	48.	04/29/1997	5,625,126	Lonberg et al.			
	49.	05/27/1997	5,633,425	Lonberg et al.			
	50.	06/17/1997	5,639,780	Lau et al.			
	51.	08/26/1997	5,661,016	Lonberg et al.			
	52.	12/02/1997	5,693,761	Queen et al.			
	53.	12/02/1997	5,693,762	Queen et al.			
	54.	03/31/1998	5,733,743	Johnson et al.			
	55.	05/12/1998	5,750,373	Garrard et al.			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)
pa- 854424

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

	56.	06/16/1998	5,766,863	Godowski et al.			
	57.	09/15/1998	5,807,715	Morrison et al.			
	58.	09/29/1998	5,814,482	Dubensky, Jr. et al.			
	59.	10/13/1998	5,821,337	Carter et al.			
	60.	12/01/1998	5,844,092	Presta et al.			
	61.	02/02/1999	5,866,692	Shitara et al.			
	62.	03/02/1999	5,877,016	Presta et al.			
	63.	04/06/1999	5,891,650	Godowski et al.			
	64.	11/09/1999	5,981,568	Kunz et al.			
	65.	12/07/1999	5,997,867	Waldmann et al.			
	66.	01/25/2000	6,017,878	Saragovi et al.			
	67.	04/25/2000	6,054,297	Carter et al.			
	68.	10/03/2000	6,127,401	Singh et al.			
	69.	11/28/2000	6,153,189	Presta et al.			
	70.	01/30/2001	6,180,370	Queen et al.			
	71.	01/30/2001	6,180,377	Morgan et al.			
	72.	04/03/2001	6,210,671	Co			
	73.	07/24/2001	6,265,150	Terstappen et al.			
	74.	09/18/2001	6,291,247	Riopelle et al.			
	75.	10/23/2001	6,306,849	Hudkins et al.			
	76.	12/18/2001	6,331,415	Cabilly et al.			
	77.	02/26/2002	6,350,861	Co et al.			
	78.	03/19/2002	6,359,130	Singh et al.			
	79.	04/23/2002	6,376,471	Lawrence, III et al.			
	80.	07/02/2002	6,413,942	Felgner et al.			
	81.	08/20/2002	6,436,908	Koch et al.			
	82.	01/14/2003	6,506,559	Fire et al.			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/ 08 (2-92) pa- 854424	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation	
							YES	NO
	83.	12/06/1989	EP 0 345 242	Europe			Abstract	
	84.	12/23/1992	EP 0 519 596	Europe				
	85.	02/03/1993	EP 0 524 968	Europe				
	86.	10/10/1988	GB 2,200,651	Great Britain				
	87.	07/30/1987	WO 87/04462	WIPO				
	88.	10/05/1989	WO 89/09225	WIPO				
	89.	07/26/1990	WO 90/07936	WIPO				
	90.	10/04/1990	WO 90/11092	WIPO				
	91.	01/10/1991	WO 91/00360	WIPO				
	92.	03/07/1991	WO 91/02805	WIPO				
	93.	10/03/1991	WO 91/14445	WIPO				
	94.	11/26/1992	WO 92/20373	WIPO				
	95.	03/04/1993	WO 93/03769	WIPO				
	96.	04/01/1993	WO 93/06213	WIPO				
	97.	05/27/1993	WO 93/10218	WIPO				
	98.	06/10/1993	WO 93/11230	WIPO				
	99.	09/30/1993	WO 93/19191	WIPO			Abstract	
	100.	12/23/1993	WO 93/25234	WIPO				
	101.	12/23/1993	WO 93/25698	WIPO				
	102.	02/17/1994	WO 94/03622	WIPO				
	103.	03/03/1994	WO 94/04690	WIPO				
	104.	06/09/1994	WO 94/12649	WIPO				
	105.	10/27/1994	WO 94/23697	WIPO				
	106.	12/22/1994	WO 94/28938	WIPO				
	107.	01/05/1995	WO 95/00655	WIPO				
	108.	03/23/1995	WO 95/07994	WIPO				
	109.	05/04/1995	WO 95/11984	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

	110.	05/26/1995	WO 95/13796	WIPO				
	111.	11/16/1995	WO 95/30763	WIPO				
	112.	06/06/1996	WO 96/17072	WIPO				
	113.	05/01/1997	WO 97/15593	WIPO				
	114.	06/19/1997	WO 97/21732	WIPO				
	115.	11/13/1997	WO 97/42338	WIPO				
	116.	02/12/1998	WO 98/06048	WIPO				
	117.	04/30/1998	WO 98/17278	WIPO				
	118.	10/21/1999	WO 99/53055	WIPO				
	119.	11/18/1999	WO 99/58572	WIPO				
	120.	09/14/2000	WO 00/53211	WIPO				
	121.	11/23/2000	WO 00/69829	WIPO				
	122.	12/07/2000	WO 00/73344	WIPO				
	123.	04/19/2001	WO 01/27160	WIPO				
	124.	04/26/2001	WO 01/29058	WIPO				
	125.	09/07/2001	WO 01/64247	WIPO				
	126.	10/25/2001	WO 01/78698	WIPO				
	127.	12/06/2001	WO 01/92513	WIPO				
	128.	02/28/2002	WO 02/15924	WIPO				
	129.	03/07/2002	WO 02/17914	WIPO				
	130.	03/14/2002	WO 02/20479	WIPO				
	131.	06/06/2002	WO 02/44321	WIPO				
	132.	12/05/2002	WO 02/96458	WIPO				

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	133.	Adey, N.B. et al. (1996). "Preparation of Second-Generation Phage Libraries" Chapter 16 <i>In Phage Display of Peptides and Proteins: A Laboratory Manual</i> Kay, B.K. et al. eds. Academic Press, Inc.: San Diego, CA pp.277-291.
	134.	Agrawal, S. et al. (1998). "Mixed Backbone Oligonucleotides: Improvement in Oligonucleotide-Induced Toxicity <i>In Vivo</i> ," <i>Antisense & Nucleic Acid Drug Development</i> 8:135-139.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
135.	Aley, K.O. et al. (1996). "Delayed Sympathectomy After a Prolonged Hyperalgesia Results in a Subsequent Enhanced Acute Hyperalgesic Response," <i>Neuroscience</i> 71(4):1083-1090.		
136.	Al-Lazikani, B. et al. (1997). "Standard Conformations for the Canonical Structures of Immunoglobulins," <i>J. Molec. Biol.</i> 273:927-948.		
137.	Aloe, L. et al. (1992). "Nerve Growth Factor and Distribution of Mast Cells in the Synovium of Adult Rats," <i>Clin. Exp. Rheumatol.</i> 10:203-204.		
138.	Aloe, L. et al. (1992). "Nerve Growth Factor in the Synovial Fluid of Patients with Chronic Arthritis," <i>Arch. Rheum.</i> 35(3):351-355.		
139.	Aloe, L. et al. (1993). "Level of Nerve Growth Factor and Distribution of Mast Cells in the Synovium of Tumour Necrosis Factor Transgenic Arthritic Mice," <i>Int. J. Tissue Reactions</i> 15(4):139-143.		
140.	Aloe, L. et al. (1995). "Effect of NGF Antibodies on Mast Cell Distribution, Histamine and Substance P Levels in the Knee Joint of TNF-Arthritic Transgenic Mice," <i>Rheumatol. Int.</i> 14:249-252.		
141.	Amann, R. et al. (1996). "Intraplantar Injection of Nerve Growth Factor into the Rat Hind Paw: Local Adema and Effects on Thermal Nociceptive Threshold," <i>Pain</i> 64:323-329.		
142.	Andreev, N.Y. et al. (1995). "Peripheral Administration of Nerve Growth Factor in the Adult Rat Produces a Thermal Hyperalgesia that Requires the Presence of Sympathetic Post-Ganglionic Neurones," <i>Pain</i> 63:109-115.		
143.	Apfel, S.C. et al. (1996). "Nerve Growth Factor Regulates the Expression of Brain-Derived Neurotrophic Factor mRNA in the Peripheral Nervous System," <i>Mol. Cell. Neurosci</i> 7:134-142.		
144.	Armour, K. L. et al. (1999). "Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities," <i>Eur. J. Immunol.</i> 29:2613-2624.		
145.	Balint, R. F. et al. (1993). "Antibody Engineering By Parsimonious Mutagenesis," <i>Gene</i> 137:109-118.		
146.	Bird, R.E. et al. (1988). "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242:423-426.		
147.	Bischoff, S.C. et al. (1992). "Effect of Nerve Growth Factor on the Release of Inflammatory Mediators by Mature Human Basophils," <i>Blood</i> 79(10):2662-2669.		
148.	Boerner, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes," <i>J. Immunol.</i> 147(1):86-95.		
149.	Boettger, M.K. et al. (2002). "Calcium-Activated Potassium Channel SK1- and IK1-like Immunoreactivity in Injured Human Sensory Neurones and its Regulation by Neurotrophic Factors," <i>Brain</i> 125:252-263.		
150.	Borsani, G. et al. (1990). "cDNA Sequence of Human β-NGF," <i>Nuc. Acids Res.</i> 18(13):4020.		
151.	Boyd, P.N. et al. (1996). "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," <i>Mol. Immunol.</i> 32(17/18):1311-1318.		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331	
		Applicant David L. SHELTON et al.		
		Filing Date October 8, 2003	Group Art Unit 1641	
		Mailing Date June 23, 2004		
	152.	Bracci Laudiero, L. et al. (1992). "Multiple Sclerosis Patients Express Increased Levels of β -Nerve Growth Factor in Cerebrospinal Fluid," <i>Neurosci Lett.</i> 147:9-12.		
	153.	Bracci-Laudiero, L. et al. (1993). "Increased Levels of NGF in Sera of Systemic Lupus Erythematosus Patients," <i>Neuroreport</i> 4(5):563-565.		
	154.	Braun, A. et al. (1998). "Role of Nerve Growth Factor in a Mouse Model of Allergic Airway Inflammation and Asthma," <i>Eur. J. Immunol.</i> 28:3240-3251.		
	155.	Brennan, T.J. et al. (1996). "Characterization of a Rat Model of Incisional Pain," <i>Pain</i> 64:493-501.		
	156.	Brennan, T.J. et al. (1998). "Role of Nerve Growth Factor in a Rat Model for Postoperative Pain," <i>Society for Neuroscience Abstracts</i> 28th Annual Meeting, Los Angeles, CA, November 7-12, 1998, 24(1):880. Abstract No. 349.4.		
	157.	Brown, B.A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.		
	158.	Buchman, V.L. et al. (1993). "Different Neurotrophins are Expressed and Act in a Developmental Sequence to Promote the Survival of Embryonic Sensory Neurons," <i>Development</i> 118:989-1001.		
	159.	Buck, D.W. et al. (1982). "Monoclonal Antibodies Specific For Cell Culture Mycoplasmas," <i>In Vitro</i> 18(4):377-381.		
	160.	Capel, P.J.A. et al. (1994). "Heterogeneity of Human IgG Fc Receptors," <i>Immunomethods</i> 4:25-34.		
	161.	Caraceni, A. et al. (2002). "Pain Measurement Tools and Methods in Clinical Research in Palliative Care: Recommendations of an Expert Working Group of the European Association of Palliative Care," <i>J. Pain Symptom. Manage.</i> 23(3):239-255.		
	162.	Chao, M.V. et al. (1986). "Gene Transfer and Molecular Cloning of the Human NGF Receptor," <i>Science</i> 232:518-521.		
	163.	Chiou, H.C. et al. (1994). "In Vivo Gene Therapy via Receptor-Mediated DNA Delivery," <i>In Gene Therapeutics: Methods and Applications of Direct Gene Transfer</i> J.A. Wolff, ed. Birkhauser, pp. 143-156.		
	164.	Chothia, C. et al. (1989). "Conformations of Immunoglobulin Hypervariable Regions," <i>Nature</i> 342:877-883.		
	165.	Chuang, H-H. et al. (2001). "Bradykinin and Nerve Growth Factor Release the Capsaicin Receptor From PtdIns(4,5)P ₂ -Mediated Inhibition," <i>Nature</i> 411:957-962.		
	166.	Chun, L.L.Y. et al. (1977). "Role of Nerve Growth Factor in the Development of Rat Sympathetic Neurons in Vitro," <i>The Journal of Cell Biology.</i> 75:705-711.		
	167.	Clackson, T. et al. (1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628.		
	168.	Clynes, R. et al. (1998). "Fc Receptors Are Required in Passive and Active Immunity to Melanoma," <i>Proc. Natl. Acad. Sci. USA</i> 95:652-656.		
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	

	169.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <i>In Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld, R. et al. eds., Alan R. Liss, Inc.: New York, NY, pp.77-96.
	170.	Connelly, S. et al. (1995). "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," <i>Human Gene Therapy</i> 6:185-193.
	171.	Crowley, C. et al. (1994). "Mice Lacking Nerve Growth Factor Display Perinatal Loss of Sensory and Sympathetic Neurons yet Develop Basal Forebrain Cholinergic Nerveurons," <i>Cell</i> 76:1001-1011.
	172.	Curiel, D.T. et al. (1992). "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," <i>Hum. Gene Ther.</i> 3:147-154.
	173.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.
	174.	Dayhoff, M.O. ed. (1978). "A Model of Evolutionary Change in Proteins" Chapter 22 <i>In Atlas of Protein Sequence and Structure</i> National Biomedical Research Foundation, Washington D.C. 5(Supp.3):345-352.
	175.	deHaas, M. et al. (1995). "Fcγ Receptors of Phagocytes," <i>J. Lab. Clin. Med.</i> 126:330-341.
	176.	DeKock, M. et al. (2001). "'Balanced Analgesia' in the Perioperative Period: Is There a Place for Ketamine?" <i>Pain</i> 92:373-380.
	177.	DiMarco, E. et al. (1993). "Nerve Growth Factor Binds to Normal Human Keratinocytes Through High and Low Affinity Receptors and Stimulates Their Growth by a Novel Autocrine Loop," <i>J. Biol. Chem.</i> 268(30):22838-22846.
	178.	Dyck, P.J. et al. (1997). "Intradermal Recombinant Human Nerve Growth Factor Induces Pressure Allodynia and Lowered Heat-Pain Threshold in Humans," <i>Neurology</i> 48:501-505.
	179.	Eide, F.F. et al. (1996). "Naturally Occurring Truncated trkB Receptors Have Dominant Inhibitory Effects on Brain-Derived Neurotrophic Factor Signaling," <i>J. Neurosci.</i> 16(10):3123-3129.
	180.	Eppstein, D.A. et al. (1985). "Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by a Cell Membrane Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 82:3688-3692.
	181.	Falcini, F. et al. (1996). "Increased Circulating Nerve Growth Factor is Directly Correlated with Disease Activity in Juvenile Chronic Arthritis," <i>Ann. Rheum. Dis.</i> 55:745-748.
	182.	Felson, D.T. et al. (1993). "The American College of Rheumatology Preliminary Core Set of Disease Activity Measures For Rheumatoid Arthritis Clinical Trial," <i>Arthritis and Rheumatism</i> 36(6):729-740.
	183.	Findeis, M.A. et al. (1993). "Targeted Delivery of DNA for Gene Therapy Via Receptors," <i>Trends Biotechnol.</i> 11:202-205.
	184.	Foster, P.A. et al. (2002). "Cellular Pathology Changes in Rat Skin Following Intradermal Injection of Nerve Growth Factor: Neutrophil-Dependent and -Independent Events," <i>J. Pathol.</i> 197:245-255.

EXAMINER:	DATE CONSIDERED:
------------------	-------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 854424	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
---------------------------------	--

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
185.	Fries, J.F. et al. (1982). "The Dimensions of Health Outcomes: The Health Assessment Questionnaire, Disability and Pain Scales," <i>J. Rheumatol.</i> 9(5):789-793.		
186.	Gazzano-Santoro, H. et al. (1996). "A Non-Radioactive Complement-Dependent Cytotoxicity Assay For Anti-CD20 Monoclonal Antibody," <i>J. Immunol. Methods</i> 202:163-171.		
187.	GenBank Accession No. L17077, "The Use of the RACE Method to Clone Hybridoma cDNA When V Region Primers Fail," created on February 7, 1995, located at < http://www.ncbi.nih.gov >, last visited on March 18, 2004, two pages.		
188.	GenBank Accession No. L17078, "The Use of the RACE Method to Clone Hybridoma cDNA When V Region Primers Fail," created on February 7, 1995, located at < http://www.ncbi.nih.gov >, last visited on March 18, 2004, one page.		
189.	GenBank Accession No. NM_002506, "Histamine Enhances the Production of Nerve Growth Factor in Human Keratinocytes," created on December 23, 2003, located at < http://www.ncbi.nih.gov >, last visited on June 11, 2004, four pages.		
190.	GenBank Accession No. U39608, "Two Distinct Monoclonal Antibodies Raised Against Mouse Beta Nerve Growth Factor: Generation of Bi-Specific Anti-Nerve Growth Factor Anti-Horseradish Peroxidase Antibodies for Use in a Homogenous Enzyme Immunoassay," created on March 25, 1999, located at < http://www.ncbi.nih.gov >, last visited on March 18, 2004, two pages.		
191.	GenBank Accession No. U39609, "Two Distinct Monoclonal Antibodies Raised Against Mouse Beta Nerve Growth Factor: Generation of Bi-Specific Anti-Nerve Growth Factor Anti-Horseradish Peroxidase Antibodies for Use in a Homogenous Enzyme Immunoassay," created January 28, 1999, located at < http://www.ncbi.nih.gov >, last visited on March 18, 2004, two pages.		
192.	Gerstenfeld, L.C. et al. (2003). "Differential Inhibition of Fracture Healing by Non-Selective and Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs," <i>J. Orthop. Res.</i> 21:670-675.		
193.	Gould, H.J. III et al. (2000). "A Possible Role for Nerve Growth Factor in the Augmentation of Sodium Channels in Models of Chronic Pain," <i>Brain Res.</i> 854:19-29.		
194.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies with High Specificity From Phage Display Libraries," <i>EMBO J.</i> 12(2):725-734.		
195.	Guyer, R.L. et al. (1976). "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors," <i>J. Immunol.</i> 117(2):587-593.		
196.	Hains, B.C. et al. (2002). "Differential Electrophysiological Effects of Brain-Derived Neurotrophic Factor on Dorsal Horn Neurons Following Chronic Spinal Cord Hemisection Injury in the Rat," <i>Neurosci Lett.</i> 320:125-128.		
197.	Haws, M.J. et al. (1996). "The Effects of Chronic Ketorolac Tromethamine (Toradol) On Wound Healing," <i>Ann. Plas. Surg.</i> 37:147-151.		
198.	Hein, J. (1990). "Unified Approach to Alignment and Phylogenesis" Chapter 39 <i>In Methods in Enzymology</i> Academic Press, Inc.: San Diego, CA 183:626-645.		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
199.	Higgins, D.G. et al. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," <i>CABIOS Communications</i> 5(2):151-153.		
200.	Higuchi, R. (1990). "Recombinant PCR" Chapter 22 <i>In PCR Protocols: A Guide to Methods and Applications</i> Innis, M.A. et al. eds. Academic Press, Inc., pp. 177-183		
201.	Holliger, P. et al. (1993). " 'Diabodies': Small Bivalent and Bispecific Antibody Fragments," <i>Proc. Natl. Acad. Sci. USA</i> 90:6444-6448.		
202.	Hongo, J. S. et al. (2000). "Antibody Binding Regions on Human Nerve Growth Factor Identified by Homolog- and Alanine-Scanning Mutagenesis," <i>Hybridoma</i> 19(3):215-227.		
203.	Hoogenboom, H. R. et al. (1991). "By-Passing Immunisation: Human Antibodies From Synthetic Repertoires of Germline V _H Gene Segments Rearranged <i>in Vitro</i> ," <i>J. Mol. Biol.</i> 227:381-388.		
204.	Horigome, K. et al. (1993). "Mediator Release from Mast Cells by Nerve Growth Factor," <i>J. Biol. Chem.</i> 268(20):14881-14887.		
205.	Hsu, T-A. et al. (1997). "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Trichoplusia ni</i> Cells," <i>J. Biol. Chem.</i> 272(14):9062-9070.		
206.	Hwang, K.J. et al. (1980). "Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study," <i>Proc. Natl. Acad. Sci. USA</i> 77(7):4030-4034.		
207.	Iannone, F. et al. (2002). "Increased Expression of Nerve Growth Factor (NGF) and High Affinity NGF Receptor (p140 TrkA) in Human Osteoarthritic Chondrocytes," <i>Rheumatology</i> 41:1413-1418.		
208.	Jefferis, R. et al. (1997). "Glycosylation of Antibody Molecules: Structural and Functional Significance," <i>Chem. Immunol.</i> 65:111-128.		
209.	Johnson, K.S. et al. (1993). "Human Antibody Engineering," <i>Current Opinion in Structural Biology</i> 3:564-571.		
210.	Jolly, D. (1994). "Viral Vector Systems for Gene Therapy," <i>Cancer Gene Therapy</i> 1(1):51-64.		
211.	Jones, P.T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.		
212.	Kabat, E.A. et al. (1991). <u>Sequences of Proteins of Immunological Interest</u> , Fifth Edition, National Institutes of Health: Bethesda, MD pp. iii-xi (Table of Contents Only.)		
213.	Kaplitt, M.G. et al. (1994). "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," <i>Nature Genetics</i> 8:148-153.		
214.	Karlsson, R. et al. (1994). "Kinetic and Concentration Analysis Using BIA Technology," <u>Methods: A Companion to Methods in Enzymology</u> Academic Press, Inc. 6:99-110.		
215.	Kassel, O. et al. (2001). "Local Increase in the Number of Mast Cells and Expression of Nerve Growth Factor in the Bronchus of Asthmatic Patients After Repeated Inhalation of Allergen at Low-Dose," <i>Clin. Exp. Allergy</i> 31:1432-1440.		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

216.	Katz, J. et al. (1999). "Measurement of Pain," <i>Surg. Clin. North Am.</i> 79(2):231-252.
217.	Kawamoto, K. et al. (2002). "Nerve Growth Factor Activates Mast Cells Through the Collaborative Interaction with Lysophosphatidylserine Expressed on the Membrane Surface of Activated Platelets," <i>J. Immunol.</i> 168:6412-6419.
218.	Kerr, B.J. et al. (2001). "A Role For the TTX-Resistant Sodium Channel Nav 1.8 in NGF-Induced Hyperalgesia, But Not Neuropathic Pain," <i>Neuroreport</i> 12(14):3077-3078.
219.	Kim, J-K. et al. (1994). "Localization of the Site of the Murine IgG1 Molecule that is Involved in Binding to the Murine Intestinal Fc Receptor," <i>Eur. J. Immunol.</i> 24:2429-2434.
220.	Kimura, O. et al. (1994). "Retroviral Delivery of DNA into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," <i>Human Gene Therapy</i> 5:845-852.
221.	Klein, R. et al. (1990). "The <i>trkB</i> Tyrosine Protein Kinase Gene Codes for a Second Neurogenic Receptor That Lacks the Catalytic Kinase Domain," <i>Cell</i> 61:647-656.
222.	Knüsel, B. et al. (1991). "K-252b Is a Selective and Nontoxic Inhibitor of Nerve Growth Factor Action on Cultured Brain Neurons," <i>J. Neurochemistry</i> 57:955-962.
223.	Knüsel, B. et al. (1992). "K-252b Selectively Potentiates Cellular Actions and <i>trk</i> Tyrosine Phosphorylation Mediated by Neurotrophin-3," <i>J. Neurochemistry</i> 59:715-722
224.	Kohler, B. et al. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
225.	Koizumi, S. et al. (1988). "K-252a: A Specific Inhibitor of the Action of Nerve Growth Factor of PC12 Cells," <i>J. Neuroscience</i> 8(2):715-721.
226.	Kuzuna, S. et al. (1975). "Evaluation of Analgesic Agents in Rats with Adjuvant Arthritis," <i>Chem Pharm. Bull.</i> 23:1184-1191.
227.	Lamballe, F. et al. (1993). " <i>trkC</i> Encodes Multiple Neurotrophin-3 Receptors with Distinct Biological Properties and Substrate Specificities," <i>EMBO J.</i> 12(8):3083-3094.
228.	Lambiase, A. et al. (2003). "Clinical Application of Nerve Growth Factor on Human Corneal Ulcer," <i>Arch. Ital. Biol.</i> 141:141-148.
229.	Leon, A. et al. (1994). "Mast Cells Synthesize, Store, and Release Nerve Growth Factor," <i>Proc. Natl. Acad. Sci. USA</i> 91:3739-3743.
230.	Levi-Montalcini, R. et al. (1968). "Nerve Growth Factor," <i>Physiol. Rev.</i> 48(3):534-569.
231.	Lewin, G.R. et al. (1994). "Peripheral and Central Mechanisms of NGF-Induced Hyperalgesia," <i>European Journal of Neuroscience</i> 6:1903-1912.
232.	Li, Y-X. et al. (1998). "Expression of a Dominant Negative TrkB Receptor, T1, Reveals a Requirement For Presynaptic Signaling in BDNF-Induced Synaptic Potentiation in Cultured Hippocampal Neurons," <i>Proc. Natl. Acad. Sci. USA</i> 95:10884-10889.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
	233.	Lindholm, D. et al. (1990). "Glucocorticoid Hormones Negatively Regulate Nerve Growth Factor Expression <i>In Vivo</i> and In Cultured Rat Fibroblasts," <i>Eur. J. Neurosci.</i> 2:795-801.	
	234.	Lindsay, R.M. (1988). "Nerve Growth Factors (NGF, BDNF) Enhance Axonal Regeneration But Are Not Required For Survival of Adult Sensory Neurons," <i>J. Neurosci.</i> 8(7):2394-2405.	
	235.	Lindsay, R.M. et al. (1989). "Nerve Growth Factor Regulates Expression of Neuropeptide Genes in Adult Sensory Neurons," <i>Nature</i> 337:362-364.	
	236.	Liu, Z.Z. et al. (1997). "Critical Role of TrkB and Brain-Derived Neurotrophic Factor in the Differentiation and Survival of Retinal Pigment Epithelium," <i>J. Neurosci.</i> 17(22):8749-8755.	
	237.	Lobuglio, A.F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 86:4220-4224.	
	238.	Lonberg, N. et al. (1995). "Human Antibodies From Transgenic Mice," <i>Int. Rev. Immunol.</i> 13:65-93.	
	239.	Mahato, R.I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm Res.</i> 14(7):853-859.	
	240.	Manni, L. et al. (1998). "Role of IL-1 β and TNF- α in the Regulation of NGF in Experimentally Induced Arthritis in Mice," <i>Rheumatol. Int.</i> 18:97-102.	
	241.	Marks, J.D. et al. (1991). "By-Passing Immunization: Human Antibodies From V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.	
	242.	Marks, J.D. et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technol.</i> 10:779-783.	
	243.	Matsuda, H. et al. (1988). "Nerve Growth Factor Promotes Human Hemopoietic Colony Growth and Differentiation," <i>Proc. Natl. Acad. Sci. USA</i> 85:6508-6512.	
	244.	Matsuda, H. et al. (1998). "Role of Nerve Growth Factor in Cutaneous Wound Healing: Accelerating Effects in Normal and Healing-Impaired Diabetic Mice," <i>J. Exp. Med.</i> 187(3):297-330.	
	245.	McCafferty, J. et al. (1990). "Phage Antibodies, Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348:552-553.	
	246.	Meenan, R.F. et al. (1982). "The Arthritis Impact Measurement Scales," <i>Arthritis and Rheumatism</i> 25(9):1048-1053.	
	247.	Michael, G.J. et al. (1997). "Nerve Growth Factor Treatment Increases Brain-Derived Neurotrophic Factor Selectively in TrkA-Expressing Dorsal Root Ganglion Cells and in Their Central Terminations Within the Spinal Cord," <i>J. Neurosci.</i> 17(21):8476-8490.	
	248.	Miletic, G. et al. (2002). "Increases in the Concentration of Brain Derived Neurotrophic Factor in the Lumbar Spinal Dorsal Horn are Associated with Pain Behavior Following Chronic Constriction Injury in Rats," <i>Neurosci Lett.</i> 319:137-140.	
	249.	Milstein, C. et al. (1983). "Hybrid Hydridomas and Their Use in Immunohistochemistry," <i>Nature</i> 305:537-539.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

250.	Møiniche, S. et al. (1997). "Time Course of Subjective Pain Ratings, and Wound and Leg Tenderness After Hysterectomy," <i>Acta Anaesthesiol. Scand.</i> 41:785-789.
251.	Møiniche, S. et al. (2002). "A Qualitative and Quantitative Systematic Review of Preemptive Analgesia for Postoperative Pain Relief," <i>Anesthesiology</i> 96:725-741.
252.	Morrison, S.L. et al. (1984). "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," <i>Proc. Natl. Acad. Sci</i> 81:6851-6855.
253.	Myers, E.W. et al. (1988). "Optimal Alignments in Linear Space," <i>CABIOS</i> 4(1):11-17.
254.	Okragly, A.J. et al. (1991). "Elevated Tryptase, Nerve Growth Factor, Neurotrophin-3 and Glial Cell Line-Derived Neurotrophic Factor Levels In the Urine of Interstitial Cystitis and Bladder Cancer Patients," <i>J. Urology</i> 161:438-442.
255.	Otten, U. et al. (1984). "Nerve Growth Factor Induces Plasma Extravasation in Rat Skin," <i>Eur. J. Pharmacol.</i> 106:199-201.
256.	Otten, U. et al. (1989). "Nerve Growth Factor Induces Growth and Differentiation of Human B Lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> 86:10059-10063.
257.	Paulus, H.E. et al. (1990). "Analysis of Improvement in Individual Rheumatoid Arthritis Patients Treated with Disease-Modifying Antirheumatic Drugs, Based on the Findings in Patients Treated with Placebo," <i>Arthritis and Rheumatism</i> 33(4):477-484.
258.	Pearce, F.L. et al. (1986). "Some Characteristics of Histamine Secretion From Rat Peritoneal Mast Cells Stimulated with Nerve Growth Factor," <i>J. Physiol.</i> 372:379-393.
259.	Pearson, C.M. et al. (1959). "Studies of Polyarthritis and Other Lesions Induced in Rats by Injection of Mycobacterial Adjuvant. I. General Clinical and Pathologic Characteristics and Some Modifying Factors," <i>Arthritis Rheum.</i> 2:440-459.
260.	Peeters, K. et al. (2001). "Production of Antibodies and Antibody Fragments in Plants," <i>Vaccine</i> 19:2756-2761.
261.	Petersen, M. et al. (1998). "Nerve Growth Factor Regulates the Expression of Bradykinin Binding Sites on Adult Sensory Neurons Via the Neurotrophin Receptor p75," <i>Neuroscience</i> 83(1):161-168.
262.	Petty, B.G. et al. (1994). "The Effect of Systemically Administered Recombinant Human Nerve Growth Factor in Healthy Human Subjects," <i>Annals Neurol.</i> 36:244-246.
263.	Philip, R. et al. (1994). "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Mol. Cell Biol.</i> 14(4):2411-2418.
264.	Pogatzki, E.M. et al. (2002). "Characterization of Aδ- and C-Fibers Innervating the Plantar Rat Hindpaw One Day After an Incision," <i>J. Neurophysiol.</i> 87:721-731.
265.	Pogatzki, E.M. et al. (2002). "Role of Rostral Medial Medulla in the Development of Primary and Secondary Hyperalgesia After Incision in the Rat," <i>Anesthesiology</i> 96:1153-1160.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
266.	Poljak, R. J. et al. (1994). "Production and Structure of Diabodies," <i>Structure</i> 2:1121-1123.		
267.	Pollock, D.P. et al. (1999). "Transgenic Milk as a Method For the Production of Recombinant Antibodies," <i>J. Immunol. Methods</i> 231:147-157.		
268.	Pons, J. et al. (1999). "Energetic Analysis of an Antigen/Antibody Interface: Alanine Scanning Mutagenesis and Double Mutant Cycles on the HyHEL-10/Lysozyme Interaction," <i>Prot. Sci.</i> 8:958-968.		
269.	Prodromou, C. et al. (1992). "Recursive PCR: A Novel Technique for Total Gene Synthesis," <i>Protein Eng.</i> 5(8):827-829.		
270.	Ravetch, J.V. et al. (1991). "Fc Receptors," <i>Ann. Rev. Immunol.</i> 9:457-492.		
271.	Raychaudhuri, S.P. et al. (1998). "Psoriatic Keratinocytes Express High Levels of Nerve Growth Factor," <i>Acta Derm Venereol.</i> 78:84-86.		
272.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.		
273.	Ro, L-S. et al. (1999). "Effect of NGF and Anti-NGF on Neuropathic Pain in Rats Following Chronic Constriction Injury of the Sciatic Nerve," <i>Pain</i> 79:265-274.		
274.	Robinson, D.F. (1971). "Comparison of Labeled Trees with Valency Three," <i>J. Comb. Theor.</i> 11:105-119.		
275.	Rossi, J.J. et al. eds. (1999). <u>Intracellular Ribozyme Applications: Principles and Protocols</u> Horizon Scientific Press: Duarte, CA pp. iii-iv (Table of Contents Only.)		
276.	Roubenoff, R. et al. (1994). "Rheumatoid Cachexia: Cytokine-Drive Hypermetabolism Accompanying Reduced Body Cell Mass in Chronic Inflammation," <i>J. Clin. Invest.</i> 93(6):2379-2386.		
277.	Roubenoff, R. et al. (1997). "Adjuvant Arthritis as a Model of Inflammatory Cachexia," <i>Arthritis Rheum.</i> 40(3):534-539.		
278.	Ruberti, F. et al. (1993). "Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for Studies Using the Neuroantibody Approach," <i>Cell. Molec. Neurobiol.</i> 13(5):559-568.		
279.	Saitou, N. et al. (1987). "The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Tree," <i>Mol. Biol. Evol.</i> 4(4):406-425.		
280.	Schwartz, F. et al. (2002). "Effect of Helium/Neon Laser Irradiation on Nerve Growth Factor Synthesis and Secretion in Skeletal Muscle Cultures," <i>J. Photochem Photobiol. B: Biology</i> 66:195-200.		
281.	Sevarino, K.A. et al. (1988). "Biosynthesis of Thyrotropin-Releasing Hormone by a Rat Medullary Thyroid Carcinoma Cell Line," <i>J. Biol. Chem.</i> 263:620-623.		
282.	Shaw, D.R. et al. (1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) To A Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138(12):4534-4538.		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92)		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
pa- 854424			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

283.	Sheets, M.D. et al. (1998). "Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens," <i>Proc. Natl. Acad. Sci. USA</i> 95:6157-6162.
284.	Smyene, R.J. et al. (1994). "Severe Sensory and Sympathetic Neuropathies in Mice Carrying a Disrupted Trk/NGF Receptor Gene," <i>Nature</i> 368:246-249.
285.	Sneath, P.H.A. et al. (1973). <u>Numerical Taxonomy the Principles and Practice of Numerical Taxonomy</u> W. H. Freeman Press: San Francisco, CA. pp. vii - ix (Table of Contents Only.)
286.	Steiner, P. et al. (1991). "Interleukin-1 β and Tumor Necrosis Factor- α Synergistically Stimulate Nerve Growth Factor Synthesis in Rat Mesangial Cells," <i>Am. J. Physiol.</i> 261:F792-F798.
287.	Taglialatela, G. et al. (1996). "Suppression of p140 ^{trkA} Does Not Abolish Nerve Growth Factor-Mediated Rescue of Serum-Free PC12 Cells," <i>J. Neurochem.</i> 66(5):1826-1835.
288.	Thompson, S.W.N. et al. (1995). "Nerve Growth Factor Induces Mechanical Allodynia Associated with Novel A Fibre-Evoked Spinal Reflex Activity and Enhanced Neurokinin-1 Receptor Activation in the Rat," <i>Pain</i> 62:219-231.
289.	Thompson, S.W.N. et al. (1999). "Brain-Derived Neurotrophic Factor is an Endogenous Modulator of Nociceptive Responses in the Spinal Cord," <i>Proc. Natl Acad. Sci USA</i> 96(14):7714-7718.
290.	Torcia, M. et al. (1996). "Nerve Growth Factor Is an Autocrine Survival Factor for Memory B Lymphocytes," <i>Cell</i> 85:345-356.
291.	Tsoufias, P. et al. (1993). "The Rat <i>trkC</i> Locus Encodes Multiple Neurogenic Receptors That Exhibit Differential Response to Neurotrophin-3 in PC12 Cells," <i>Neuron</i> 10:975-990.
292.	Ueyama, T. et al. (1993). "Production of Nerve Growth Factor by Cultured Vascular Smooth Muscle Cells From Spontaneously Hypertensive and Wistar-Kyoto Rats," <i>J. Hypertens.</i> 11:1061-1065.
293.	Ullrich, A. et al. (1983). "Human β -Nerve Growth Factor Gene Sequence Highly Homologous to That of Mouse," <i>Nature</i> 303:821-825.
294.	Umana, P. et al. (1999). "Engineered Glycoforms of an Antineuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity," <i>Mature Biotech.</i> 17:176-180.
295.	Urfer, R. et al. (1997). "Specificity Determinants in Neurotrophin-3 and Design of Nerve Growth Factor-Based trkC Agonists by Changing Central β -Strand Bundle Residues to Their Neurotrophin-3 Analogs," <i>Biochem.</i> 36:4775-4781.
296.	Valenzuela, D.M. et al. (1993). "Alternative Forms of Rat TrkC With Different Functional Capabilities," <i>Neuron</i> 10:963-974.
297.	Vaughan, T.J. et al. (1996). "Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-Immunized Phage Display Library," <i>Nature Biotechnology</i> 14:309-314.
298.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712000400	Application Number 10/682,331
		Applicant David L. SHELTON et al.	
		Filing Date October 8, 2003	Group Art Unit 1641
		Mailing Date June 23, 2004	
	299.	Waterhouse, P. et al. (1993). "Combinatorial Infection and <i>in vivo</i> Recombination: A Strategy for Making Large Phage Antibody Repertoires," <i>Nucl. Acids Res.</i> 21(9):2265-2266.	
	300.	Wilbur, W.J. et al. (1983). "Rapid Similarity Searches of Nucleic Acid and Protein Data Banks," <i>Proc. Natl. Acad. Sci. USA</i> 80:726-730.	
	301.	Winter, G. et al. (1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299.	
	302.	Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455.	
	303.	Wittwer, A.J. et al. (1990). "Glycosylation at Asn-184 Inhibits the Conversion of Single-Chain to Two-Chain Tissue-Type Plasminogen Activator by Plasmin," <i>Biochem.</i> 29:4175-4180.	
	304.	Woffendin, C. et al. (1994). "Nonviral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene into Primary Human T Cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:11581-11585.	
	305.	Woolf, C.J. et al. (1996). "Peripheral Cell Types Contributing to the Hyperalgesic Action of Nerve Growth Factor in Inflammation," <i>J. Neurosci.</i> 16(8):2716-2723.	
	306.	Woolf, N.J. et al. (2001). "Elevation of Nerve Growth Factor and Antisense Knockdown of TrkA Receptor during Contextual Memory Consolidation," <i>J. Neurosci.</i> 21(3):1047-1055.	
	307.	Wright, A. et al. (1997). "Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering," <i>TibTECH</i> 15:26-32.	
	308.	Wu, C.H. et al. (1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements <i>in Vivo</i> ," <i>J. Biol. Chem.</i> 264:16985-16987.	
	309.	Wu, G.Y. et al. (1991). "Receptor-Mediated Gene Delivery <i>in Vivo</i> : Partial Correction of Genetic Analbuminemia in Nagase Rats," <i>J. Biol. Chem.</i> 266(22):14338-14342.	
	310.	Wu, G.Y. et al. (1994). "Incorporation of Adenovirus into a Ligand-Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," <i>J. Biol. Chem.</i> 269(15):11542-11546.	
	311.	Wyss, D.F. et al. (1996). "The Structural Role of Sugars in Glycoproteins," <i>Current Opin. Biotech</i> 7:409-416.	
	312.	Yamamoto, T. et al. (2001). "Spinal <i>N</i> -acetyl- α -linked Acidic Dipeptidase (NAALADase) Inhibition Attenuates Mechanical Allodynia Induced by Paw Carrageenan Injection in the Rat," <i>Brain Res.</i> 909:138-144.	
	313.	Yan, Q. et al. (1991). "Hypotension Induced by Intravascular Administration of Nerve Growth Factor in the Rat," <i>Clin. Sci.</i> 80:565-569.	
	314.	Zenke, M. et al. (1990). "Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hematopoietic Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3655-3659.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 854424		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712000400	Application Number 10/682,331
	Applicant David L. SHELTON et al.	
	Filing Date October 8, 2003	Group Art Unit 1641
	Mailing Date June 23, 2004	

	315.	Zola, H. (1987). "Using Monoclonal Antibodies: Soluble Antigens" Chapter 6 <i>In</i> <u>Monocolonal Antibodies: A Manual of Techniques</u> CRC Press, Inc. pp. 147-158.
--	------	---

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.